Levine Cancer
@LevineCancer
Followers
2K
Following
2K
Media
819
Statuses
2K
Levine Cancer is home to top providers, cutting-edge treatments and groundbreaking clinical trials. Our expert care helps patients heal – and thrive.
Based in Charlotte, NC
Joined February 2019
It’s a game changer in the fight against cancer – but what is proton beam therapy and how does it work? Watch this to learn more about this highly precise treatment option for kids and adults with complex diagnoses.
0
0
1
Join us in cheering on our Crucial Catch captains in their fight against cancer with a #KeepPounding
@AtriumHealth | @LevineCancer
8
35
491
Together with @AtriumHealth , we turned the field into a place of courage, honoring cancer survivors, fighters, and their incredible support teams with a heartfelt family reunion dinner. 💙 @LevineCancer | #KeepPounding
3
17
109
A powerful moment of support as Panthers players delivered Crucial Catch gear and self-care kits to patients at @AtriumHealth Levine Cancer Institute. 💙 @LevineCancer | #KeepPounding
5
36
279
We’re proud of you @RandyMoss and honored to be part of your journey.
Our own @RandyMoss opens up to Robin Roberts about his cancer diagnosis and journey to recovery. Full interview on Thursday in the 8 AM ET hour on @GMA.
2
1
3
Survivorship begins at #cancer diagnosis! Required registration by Aug 28 to save your seat for this community lunch event hosted by @LevineCancer for a day of Empowerment & Wellness for Survivors, Thrivers & CarePartners 💚 No-cost: 👉🏼 https://t.co/rruC9T3mtU
#Survivorship
3
1
2
Survivorship begins at #cancer diagnosis. Join @LevineCancer Sat, Sept 6 for a day of Empowerment & Wellness for Survivors, Thrivers & CarePartners 💚 📍 In-person | 📝 Register by Aug 28👉🏼 https://t.co/rruC9T2OEm
#Survivorship #CancerSurvivor #ThriverStrong #CarePartnerSupport
1
1
1
Top Papers (7/10): Dr. Nilanjan Ghosh, MD, PhD of @LevineCancer made the list of top papers of 2024 in the Department of Internal Medicine with his paper on treatment of CLL! https://t.co/JR5BcFCJ7L
onlinelibrary.wiley.com
Click on the article title to read more.
0
1
2
Congrats to our cancer program leader Dr. Ruben Mesa (@mpdrc) on earning the prestigious Ernest Beutler Lecture and Prize! Dr. Mesa has been a pioneer in the groundbreaking research & development of new therapies for myeloproliferative neoplasms (MPNs). @AtriumHealthWFB
ASH is proud to recognize 11 hematologists whose groundbreaking research and leadership have transformed the understanding and care of blood disorders. Congratulations to all! 👏 🔗 https://t.co/qVmyQtM4QJ
#Hematology #ASHAwards
1
1
10
Potentially game-changing work underway for multiple myeloma, led by @PlasmaCellPete and presented at #ASCO25 👏👇
After terminally ill patients tried a last-ditch blood cancer treatment, doctors are talking about a potential cure.
1
2
2
A possible game-changer for those battling relapsed/refractory multiple myeloma (RRMM). 🩸Our study shows that 33% of patients treated with cilta-cel have remained progression-free for ≥5 years. #ASCO25 Link: https://t.co/MA1BE7CJDQ
0
1
1
Exciting news for childhood cancer survivors! A new AI model using simple 10-second ECGs can predict the risk of developing cardiomyopathy within 5 years. This can help identify those needing early heart screenings. 💖 #ASCO25 @AtriumHealthWFB Link: https://t.co/D3zLxgHmM2
0
0
2
Ropeginterferon Alfa-2b Demonstrates Superior Efficacy & Safety to Anagrelide as 2L for ET - honored to have shared this yesterday during #ASCO25 @AtriumHealthWFB Comprehensive Cancer Center @LevineCancer @PharmaEssentia
dailynews.ascopubs.org
The phase 3 SURPASS-ET trial results show superior efficacy and safety of ropeginterferon alfa-2b compared with anagrelide as second-line therapy for essential thrombocythemia (Abstract 6500).
2
9
32
Small steps, big impacts for cancer survivors! Our study shows the AH-HA tool significantly boosts CV health discussions and even helps with weight loss. Survivors using AH-HA saw more weight reduction compared to usual care. @AtriumHealthWFB #ASCO25 Link: https://t.co/eJkSlfvobv
1
1
2
Promising results for patients with essential thrombocythemia (ET) 🩸Dr. Ruben Mesa (@mpdrc) highlights Phase 3 SURPASS-ET trial of ropeginterferon at #ASCO25, offering new hope for ET patients with better blood count control & reduced JAK2 mutation. Link: https://t.co/sbW2xcY67T
1
4
7
Our @LevineCancer @AtriumHealthWFB crew with the always-inspiring @ASCO CEO @CliffordHudis & our incredible leader @ASCOPres Dr Zon! #asco2025
3
5
17
Pre-treatment DPYD genotyping can save 💵 & reduce severe side effects from fluoropyrimidine therapy. By identifying genetic variants beforehand, hospitals can cut costs & improve patient outcomes. 🏥💊 #ASCO25 Link: https://t.co/bCVPFn1Xh0
0
1
3
Our largest study yet on #DPYD genotype-guided chemotherapy shows that personalized dosing can help reduce severe side effects and hospitalizations. This means safer, more effective treatment options for patients with DPYD variants. 💊🧬 #ASCO25 Link: https://t.co/lcPW9GXygr
0
1
4
Older cancer survivors tried muscadine grape extract for 12 weeks. While it didn't beat fatigue or boost quality of life, it did improve physical function & gait speed. Next steps, find out how it affects oxidative stress & inflammation. 🍇 #ASCO25 Link: https://t.co/irMWNpz2Gc
0
1
4
Neuro-onc study alert 🧠 @AshleySumrallMD presents research that shows dordaviprone (ONC201) is effective and safe for treating recurrent H3 K27M-mutant diffuse midline glioma. With positive responses in both adults and kids, it offers hope. #ASCO25 Link: https://t.co/1POusGe4b2
1
4
6